Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

After more than a decade in charge of the most influential organization representing the U.S. pharmaceutical industry, the ...

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...

With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...

Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the ...

Cognito Therapeutics is partnering with a nonprofit to “Change the D-Word,” aiming to eliminate the use of “dementia,” a ...

For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand ...

U.S. Olympic gold medal-winning athlete Lindsey Vonn is once again teaming up with infectious disease biopharma Invivyd for a ...

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...

One year into his tumultuous tenure as the FDA’s commissioner, Marty Makary, M.D., has laid out ambitious internal goals and ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...